Introduction Impurity Control Strategies Under ICH Q3A and Q3B establish a risk-based regulatory framework used by global health authorities to […]
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Introduction Outsourcing your first generic drug project to a CDMO requires a structured technical transition that covers candidate characterization, technology
Outsourcing Your First Generic Drug Project to a CDMO: A Step-by-Step Sponsor Guide Read More »
Introduction Container Closure System Selection and Qualification for generic parenteral drug products involves the systematic evaluation and validation of primary
Introduction End-to-End ANDA Analytical Package Development for a complex generic suspension requires an integrated analytical framework that connects qualitative (Q1)
Introduction: FDA and Health Canada Inspection Readiness for Testing Laboratories means maintaining a laboratory in a state where analytical activities,
Preparing for an FDA or Health Canada Inspection: Your Testing Lab’s Role Read More »
Introduction Technology Transfer from Innovator to Generic CDMO is a structured and highly regulated process involving the systematic translation of
Introduction Bioanalytical CRO services for Phase I First-in-Human studies provide the quantitative bioanalytical infrastructure necessary to validate drug concentration assays,
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a
Introduction: Generic Drug Development for Inhaled Drug Products requires a development strategy that connects formulation science, device engineering, analytical characterization,
Introduction Sequence Confirmation Services for Synthetic Therapeutic Peptides provide definitive verification of the primary amino acid sequence, terminal modifications, and
